Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJFBQ1)

Drug Name

9-phenanthrol Drug Info

Synonyms

Phenanthren-9-ol; 9-PHENANTHROL; 9-Hydroxyphenanthrene; 9-Phenanthrenol; 484-17-3; UNII-9FYU45OV9H; NSC 50554; CCRIS 1840; EINECS 207-602-4; BRN 2047057; 9FYU45OV9H; CHEBI:28820; DZKIUEHLEXLYKM-UHFFFAOYSA-N; AC1Q7B0Z; AC1L1UR8; DSSTox_RID_82439; DSSTox_CID_27592; ACMC-1AD67; DSSTox_GSID_47592; 4-06-00-04937 (Beilstein Handbook Reference); SCHEMBL508755; 9-Phenanthrol, technical grade; GTPL4114; CHEMBL2407182; DTXSID9047592; CTK1D6170; DZKIUEHLEXLYKM-UHFFFAOYSA-; MolPort-001-787-230; ZINC967824; KS-000018CG; NSC50554; AC1Q7986

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 10229
ChEBI ID: CHEBI:28820
CAS Number: CAS 484-17-3
TTD Drug ID: DMJFBQ1

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Investigative Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Long transient receptor potential channel 4 (TRPM4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[6]
PIP2	DMOZV7N	Discovery agent	N.A.	Investigative	[7]
adenosine diphosphate	DMFUHKP	N. A.	N. A.	Investigative	[6]
decavanadate	DMLT1N3	Discovery agent	N.A.	Investigative	[8]
BTP2	DMNM63G	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------

Drug(s) Affected By Transient receptor potential cation channel subfamily M member 5 (TRPM5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[10]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[11]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[12]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[13]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[14]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Affected By Complement C3 (C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[16]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[17]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[18]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[19]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[20]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[22]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[23]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[24]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Nuclear receptor-interacting protein 1 (NRIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[16]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[25]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[26]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[27]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[28]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[29]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[30]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[10]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[31]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[32]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Protein jagged-1 (JAG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[33]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[34]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[35]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[36]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[37]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[28]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[38]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[26]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[39]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[40]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Sodium channel protein type 5 subunit alpha (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[41]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[42]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[43]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[44]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[45]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[46]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[47]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[48]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[49]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[50]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[51]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[52]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[53]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[54]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[55]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[56]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[57]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[58]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[59]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[60]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[61]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[61]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[61]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[62]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[63]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[64]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[65]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[66]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[67]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[41]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 2A13 (CYP2A13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[68]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[69]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[69]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[70]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[15]
HELENALIN	DMMCI4H	N. A.	N. A.	Terminated	[71]
Acenaphthenol	DMT3QYZ	N. A.	N. A.	Investigative	[72]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[73]
BRN-3548355	DM4KXT0	N. A.	N. A.	Investigative	[73]
Chrysin	DM7V2LG	Discovery agent	N.A.	Investigative	[74]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Estrogen receptor beta (ESR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[16]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[75]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[76]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[77]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[78]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[79]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[80]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[81]
Mestranol	DMG3F94	Contraception	QA21	Approved	[82]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[83]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[52]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[84]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[85]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[86]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[87]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[88]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[89]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[70]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[90]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[91]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Long transient receptor potential channel 4 (TRPM4)	TTJ2HKA	TRPM4_HUMAN	Blocker (channel blocker)	[2]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Complement C3 (C3)	OTCH5GS0	CO3_HUMAN	Gene/Protein Processing	[3]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Regulation of Drug Effects	[4]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Regulation of Drug Effects	[4]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Regulation of Drug Effects	[4]
Cytochrome P450 2A13 (CYP2A13)	OTVUDLT3	CP2AD_HUMAN	Regulation of Drug Effects	[4]
Estrogen receptor beta (ESR2)	OTXNR2WQ	ESR2_HUMAN	Drug Response	[3]
Nuclear receptor-interacting protein 1 (NRIP1)	OTIZOJQV	NRIP1_HUMAN	Gene/Protein Processing	[3]
Protein jagged-1 (JAG1)	OT3LGT6K	JAG1_HUMAN	Gene/Protein Processing	[3]
Sodium channel protein type 5 subunit alpha (SCN5A)	OTGYZWR6	SCN5A_HUMAN	Gene/Protein Processing	[5]
Transient receptor potential cation channel subfamily M member 5 (TRPM5)	OTLYEES9	TRPM5_HUMAN	Gene/Protein Processing	[2]

------------------------------------------------------------------------------------

References

1	The TRPM4 channel inhibitor 9-phenanthrol. Br J Pharmacol. 2014 Apr;171(7):1600-13.
2	9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels. Br J Pharmacol. 2008 Apr;153(8):1697-705.
3	Differential action of monohydroxylated polycyclic aromatic hydrocarbons with estrogen receptors and . Toxicol Sci. 2013 Apr;132(2):359-67. doi: 10.1093/toxsci/kfs287. Epub 2012 Sep 18.
4	Structure-Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6. Chem Res Toxicol. 2016 Jun 20;29(6):1029-40. doi: 10.1021/acs.chemrestox.6b00083. Epub 2016 May 12.
5	The transient receptor potential melastatin 4 channel inhibitor 9-phenanthrol modulates cardiac sodium channel. Br J Pharmacol. 2018 Dec;175(23):4325-4337. doi: 10.1111/bph.14490. Epub 2018 Oct 14.
6	Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5.
7	Phosphatidylinositol 4,5-bisphosphate rescues TRPM4 channels from desensitization. J Biol Chem. 2005 Nov 25;280(47):39185-92.
8	Decavanadate modulates gating of TRPM4 cation channels. J Physiol. 2004 Nov 1;560(Pt 3):753-65.
9	A pyrazole derivative potently inhibits lymphocyte Ca2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 ch... Mol Pharmacol. 2006 Apr;69(4):1413-20.
10	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
11	Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
12	17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
13	Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
14	CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
15	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
16	Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
17	Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
18	The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
19	Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
20	Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
21	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
22	Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
23	A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
24	Thalidomide therapy. An open trial. Int J Dermatol. 1985 Mar;24(2):131-4. doi: 10.1111/j.1365-4362.1985.tb05400.x.
25	Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
26	A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
27	Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
28	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
29	Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
30	Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
31	PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
32	Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. J Biol Chem. 2015 Jun 5;290(23):14418-29. doi: 10.1074/jbc.M115.643015. Epub 2015 Apr 25.
33	Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
34	Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
35	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
36	Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
37	How benzene and its metabolites affect human marrow derived mesenchymal stem cells. Toxicol Lett. 2012 Oct 17;214(2):145-53. doi: 10.1016/j.toxlet.2012.08.015. Epub 2012 Aug 30.
38	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
39	NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
40	Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
41	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
42	Ethnic-Related Sodium Voltage-Gated Channel Subunit 5 Polymorphisms Shape the In Vitro Pharmacological Action of Amiodarone upon Na(v)1.5. Mol Pharmacol. 2021 Jun;99(6):448-459. doi: 10.1124/molpharm.120.000176. Epub 2021 Apr 6.
43	Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):338-41. doi: 10.1046/j.1460-9592.2003.00045.x.
44	Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018 Oct 26;293(43):16546-16558. doi: 10.1074/jbc.RA118.004929. Epub 2018 Sep 14.
45	Regulatory effects of non-steroidal anti-inflammatory drugs on cardiac ion channels Nav1.5 and Kv11.1. Chem Biol Interact. 2021 Apr 1;338:109425. doi: 10.1016/j.cbi.2021.109425. Epub 2021 Feb 19.
46	Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
47	Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
48	Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2016 Apr 1;296:42-53. doi: 10.1016/j.taap.2016.01.015. Epub 2016 Jan 25.
49	Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
50	Modulation of the heart's electrical properties by the anticonvulsant drug retigabine. Toxicol Appl Pharmacol. 2017 Aug 15;329:309-317. doi: 10.1016/j.taap.2017.06.018. Epub 2017 Jun 20.
51	Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
52	Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
53	Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
54	Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
55	Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
56	Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
57	Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
58	Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
59	The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
60	Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
61	In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
62	Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
63	Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
64	Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
65	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
66	Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
67	Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
68	CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
69	Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
70	Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
71	In vitro metabolism of helenalin and its inhibitory effect on human cytochrome P450 activity. Arch Toxicol. 2022 Mar;96(3):793-808. doi: 10.1007/s00204-021-03218-6. Epub 2022 Jan 6.
72	Oxidation of Acenaphthene and Acenaphthylene by Human Cytochrome P450 Enzymes. Chem Res Toxicol. 2015 Feb 16;28(2):268-78.
73	Functional characterization of CYP2A13 polymorphisms. Xenobiotica. 2007 Dec;37(12):1439-49. doi: 10.1080/00498250701666265.
74	Oxidation of Flavone, 5-Hydroxyflavone, and 5,7-Dihydroxyflavone to Mono-, Di-, and Tri-Hydroxyflavones by Human Cytochrome P450 Enzymes. Chem Res Toxicol. 2019 Jun 17;32(6):1268-1280. doi: 10.1021/acs.chemrestox.9b00078. Epub 2019 Apr 17.
75	Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects. Biomed Pharmacother. 2010 Feb;64(2):88-92. doi: 10.1016/j.biopha.2009.06.010. Epub 2009 Oct 23.
76	Quercetin exerts bidirectional regulation effects on the efficacy of tamoxifen in estrogen receptor-positive breast cancer therapy: An in vitro study. Environ Toxicol. 2020 Nov;35(11):1179-1193. doi: 10.1002/tox.22983. Epub 2020 Jun 12.
77	Comparison of an array of in vitro assays for the assessment of the estrogenic potential of natural and synthetic estrogens, phytoestrogens and xenoestrogens. Toxicology. 2001 Sep 14;166(1-2):79-89. doi: 10.1016/s0300-483x(01)00437-1.
78	Estrogenic effects of natural and synthetic compounds including tibolone assessed in Saccharomyces cerevisiae expressing the human estrogen alpha and beta receptors. FASEB J. 2006 Jul;20(9):1552-4. doi: 10.1096/fj.05-5413fje. Epub 2006 May 23.
79	Comparison of relative binding affinities to fish and mammalian estrogen receptors: the regulatory implications. Toxicol Lett. 2010 Feb 15;192(3):298-315. doi: 10.1016/j.toxlet.2009.11.004. Epub 2009 Nov 12.
80	Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. Environ Health Perspect. 2004 Apr;112(5):524-31. doi: 10.1289/ehp.6649.
81	Valproic acid and its derivatives enhanced estrogenic activity but not androgenic activity in a structure dependent manner. Reprod Toxicol. 2013 Dec;42:49-57. doi: 10.1016/j.reprotox.2013.07.019. Epub 2013 Jul 26.
82	Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids. Biosci Biotechnol Biochem. 2002 Jul;66(7):1479-87. doi: 10.1271/bbb.66.1479.
83	Arylpiperazines for management of benign prostatic hyperplasia: design, synthesis, quantitative structure-activity relationships, and pharmacokinetic studies. J Med Chem. 2011 Jan 13;54(1):302-11. doi: 10.1021/jm101163m. Epub 2010 Dec 3.
84	Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
85	Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
86	Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
87	In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
88	Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
89	Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
90	Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
91	Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.